Table 1.

Toxicity and anti-inflammatory activity of target compounds.

No.	The survival rate (%) of BV2 microglia cells treated with compounds (10 μM) by CCK-8	Inhibition rate (%) against TNF-α treated with compounds (10 μM) + LPS (1 μg/mL)
6a	95.4 ± 3.4	68.4 ± 2.5
6b	92.0 ± 2.1	57.5 ± 2.8
6c	96.7 ± 3.6	48.2 ± 5.6
6d	86.9 ± 2.2	51.4 ± 1.6
6e	90.3 ± 1.5	53.0 ± 2.8
6f	93.1 ± 4.5	69.9 ± 3.2
6g	90.3 ± 3.7	44.0 ± 3.7
6h	91.3 ± 3.6	67.2 ± 3.2
6i	90.6 ± 2.7	72.6 ± 5.1
6j	91.4 ± 2.5	46.0 ± 0.4
6k	89.5 ± 2.0	36.5 ± 2.4
6l	92.8 ± 5.5	32.0 ± 4.8
6m	95.5 ± 2.1	80.5 ± 1.9
6n	88.4 ± 2.1	65.8 ± 1.7
7a	95.8 ± 2.6	45.2 ± 2.1
7b	92.2 ± 4.3	59.5 ± 1.7
7c	89.5 ± 1.7	48.6 ± 3.5
PDTC (30 μM)	–	58.1 ± 1.6
LPS (1 μg/mL)	–	0

PDTC was used as a positive control.